Background and objectives: One of the leading causes of mortality and morbidity in people over the age of 50 is stroke. The acceptance of transcatheter aortic valve replacement (TAVR) as a treatment option for severe symptomatic aortic stenosis (AS) has increased as a result of numerous randomized clinical trials comparing surgical aortic valve replacement (SAVR) and TAVR in high- and intermediate-risk patients, showing comparable clinical outcomes and valve hemodynamics. Materials and Methods: An electronic search of Medline, Google Scholar and Cochrane Central was carried out from their inception to 28 September 2022 without any language restrictions. Results: Our meta-analysis demonstrated that, as compared with SAVR, TAVR was not linked with a lower stroke ratio or stroke mortality. It is clear from this that the SAVR intervention techniques applied in the six studies were successful in reducing cardiogenic consequences over time. Conclusions: A significantly decreased rate of mortality from cardiogenic causes was associated with SAVR. Additionally, when TAVR and SAVR were compared for stroke mortality, the results were nonsignificant with a p value of 0.57, indicating that none of these procedures could decrease stroke-related mortality.

Review question / Objective: If TAVR is a viable treatment option to prevent early stroke mortality in patients of low and intermediate risk compared to SAVR? It is not viable in the long-term at 5 or over years? Condition being studied: Transcatheter aortic valve replacement (TAVR), surgical aortic valve replacement (SAVR), stroke, MI. METHODS Search strategy: An electronic search of MEDLINE, Google Scholar, and Cochrane INPLASY 1 International Platform of Registered Systematic Review and Meta-analysis Protocols INPLASY PROTOCOL TAVR vs SAVR long-term mortality due to stroke and MI: A meta-analysis during COVID 19 pandemic Serbanoiu, LI 1 ; Ion, AC 2 ; Plesu, E 3 ; Busnatu, SS 4 ; Andrei, CL 5 . To cite: Serbanoiu et al. TAVR vs SAVR long-term mortality due to stroke and MI: A metaanalysis during COVID 19 pandemic. Inplasy protocol 2022110110.